Short CommunicationHLA-B*58 01 carrier status of Hmong in Minnesota: first in Hmong genotyping for prevalence of this biomarker of risk for severe cutaneous adverse reactions caused by allopurinolPeng, Keruia,,*; Bjork, Jonathanb,,c,,d,,*; Wen, Ya-Fenga; Roman, Youssef M.e; Culhane-Pera, Kathleenf; Lo, May Xiag; Gertner, Elieb,,c; Straka, Robert J.aAuthor Information aDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis bSection of Rheumatology, Regions Hospital, St Paul cDivision of Rheumatology, University of Minnesota, Minneapolis dDepartment of Internal Medicine, University of Minnesota, Minneapolis, Minnesota eDepartment of Pharmacotherapy and Outcomes Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia fMinnesota Community Care gPhalen Family Pharmacy, St Paul, Minnesota, USA Received 7 June 2019 Accepted 20 September 2019 * Dr. Kerui Peng and Dr. Jonathan Bjork contributed equally to the writing of this article. Portions of this work have been presented as an abstract at the 2018 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, Seattle, WA, October 2018. Correspondence to Robert J. Straka, PharmD, FCCP, Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, 308 Harvard St SE, Minneapolis, MN 55455, USA, Tel: +612 624 5663; fax: +612 625 3927; e-mail: firstname.lastname@example.org Pharmacogenetics and Genomics: February 2020 - Volume 30 - Issue 2 - p 21-25 doi: 10.1097/FPC.0000000000000391 Buy Metrics Abstract Allopurinol, a common medication to treat gout, is associated with severe cutaneous adverse reactions, and the occurrence is highly predicted by an individual’s HLA-B*58:01 carrier status. Guidelines endorse preemptive testing in select Asian populations before initiating allopurinol. The Hmong, an Asian subpopulation originally from China who now live dispersed around the world, have a 2.5-fold higher risk of gout when compared to non-Hmong in Minnesota. Given the concern for severe cutaneous adverse reactions when prescribing allopurinol, we quantified the carrier status of HLA-B*58:01 in Hmong from two independent cohorts in Minnesota. Using a community-based participatory research approach, HLA-B*58:01 carrier status was determined in 49 US-born Hmong without a history of gout or allopurinol use. Further, 47 Hmong patients undergoing clinical evaluation to receive gout pharmacotherapy were also tested. The frequency of HLA-B*58:01 positive carrier status in these two cohorts were compared to published data from a Han Chinese (n = 2910) and a Korean cohort (n = 485) using a Fisher’s exact test with a Bonferroni-corrected P-value <0.025 for significance. With one uninterpretable result, we identified two out of 95 people (2.1%) who carried HLA-B*58:01. This 2.1% incidence in these Hmong adults is notably lower than Han Chinese (19.6%, P < 0.0001) and Korean (12.2%, P = 0.0016) populations. Though commonly understood to be of Chinese descent, the lower prevalence within the Hmong underscores the risk of generalizing genotypic findings from Chinese to Asian subpopulations. We suggest no change to the current guidelines recommending which populations should be tested for HLA-B*58:01 before allopurinol use until further validation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.